New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid

摘要

A process for the synthesis of ivabradine (3-{3-[{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino]-propyl}-7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one) of formula (I) is disclosed, wherein a compound of formula (V) is subjected to a catalytic hydrogenation reaction to obtain a compound of formula (VI), and then the compound of formula (VI) thereby obtained is subjected to a reaction with the compound of formula (VII) in the presence of hydrogen and a catalyst (such as palladium-on-carbon), to yield directly, after filtering off the catalyst and isolation, the addition salt of ivabradine with the acid HX (such as hydrochloric acid), which is optionally subjection to the action of a base to obtain free ivabradine. The substituents for the variables shown in formulae (I), (V), (VI) & (VII) are as defined in the specification. Also disclosed are pharmaceutical composition comprising an alpha crystalline form of ivabradine hydrochloride, which are suitable for use as bradycardiacs, and may be used in the treatment of myocardial ischaemia (such as angina pectoris), myocardial infract and associated rhythm disturbances and in the treatment of heart failure.